Altai Protocol Library
1041 protocols and counting
All protocols with references and links
All protocols reviewed by a Medical Oncologist/Hematologist
All protocols in major guidelines included
Ability to create your own protocols
New Drug: Dostarlimab-gxly for dMMR endometrial cancer
Study: Multicenter, multicohort, open-abel trial (GARNET) dMMR recurrent or advanced endometrial cancer who had progressed on or after a platinum-containing regimen Dostarlimab-gxly q21 (n=141) Efficacy: ORR: 45.4% [37.0-54.0]; CR: 15.6%;
New Drug: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Study: International, open-label, phase 3 trial Metastatic CRPC, previously treated with at least one androgen-receptor-pathway inhibitor and one or two taxane regimens 177Lu-PSMA-617 (7.4 GBq every 6 weeks for four
New Drug: Pacritinib for Myelofibrosis
Study: International, multicenter, randomized, double-blind trial (PERSIST-2) Intermediate-1, intermediate-2, or high-risk disease myelofibrozis Pacritinib 400 mg (n=75) vs pacritinib 200 mg BID (n=74) vs BAT (n=72 Efficacy: >35% spleen volume